Core Viewpoint - Advanced Biomed Inc. announced a reverse stock split at a ratio of 1 for 20 shares, effective February 20, 2026, to comply with Nasdaq Listing Rule 5550(a)(2) [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by a majority of the voting power on January 12, 2026, with the board finalizing the ratio on January 30, 2026 [2]. - The objective of the reverse split is to enable the company to meet the minimum bid price requirement of $1.00 per share on Nasdaq [3]. - Following the reverse split, the total issued and outstanding common shares will decrease from 27,290,710 to approximately 1,364,536 shares [6]. Group 2: Shareholder Impact - Each 20 shares will convert into one share, maintaining the par value of US$0.001, and will not alter stockholders' percentage ownership, except for minor changes due to fractional shares [4]. - No fractional shares will be issued; stockholders will receive one full share instead of any fractional share resulting from the split [5]. Group 3: Company Overview - Advanced Biomed Inc. is a biotechnology company focused on innovative biomedical products for precision medicine and advanced diagnostics [1][7]. - The company operates through a subsidiary in Taiwan and has developed a proprietary microfluidic platform for advanced circulating tumor cell detection and analysis [8].

Strategic Progress - In December 2025, the company announced the sale of its 100% stake in its Hong Kong subsidiary, Advanced Biomed (HK) Limited, for a total consideration of $23,000, along with the transfer of related intellectual property [2] - The CEO, Dr. Lu Yi, stated that this move aims to address changes in the regulatory environment, with future clinical trials to be concentrated through the Taiwan subsidiary [2] - This asset divestiture may impact the company's future business layout and operational focus [2] Stock and Financial Performance - In January 2026, the stock experienced significant volatility, with a notable drop of 5.95% on January 8, closing at $0.330 per share, accompanied by low trading volume of 1,277 shares and a fluctuation of 8.20% [3] - Financial reports for the same period indicated zero revenue, a net loss of $12,925.94, earnings per share of $0.00, and a price-to-earnings ratio of -2.14, reflecting a continued state of losses [3] - Future areas of interest include the execution progress of strategic adjustments, financial improvement, and overall dynamics in the life sciences industry [3]

Core Insights - Advanced Biomed Inc. has entered into a clinical research collaboration with Chi-Mei Medical Center to conduct a 120-case feasibility study on its A+PerfusC platform, aimed at evaluating predictive accuracy in oncology treatment selection [1][2]. Group 1: Study Details - The feasibility study is a non-interventional clinical research project approved by the Institutional Review Board, with case collection starting in early February 2026 and full completion targeted by year-end 2026 [2]. - Interim comparative data from the study is expected in May–June 2026, focusing on the correlation between drug sensitivity results from the A+PerfusC platform and actual patient clinical outcomes [2][4]. Group 2: Technological Advantages - The A+PerfusC platform utilizes label-free microfluidic technology to isolate high-viability circulating tumor cells, enabling automated 3D culture arrays for parallel drug testing, which addresses limitations of traditional 2D models and xenograft animal models [3][4]. - This innovative approach aims to reduce the time to evidence-based treatment decisions and minimize patient exposure to ineffective therapies [3]. Group 3: Collaboration and Future Plans - The collaboration with Chi-Mei Medical Center will involve joint clinical research and commercial development, with both parties sharing rights to project-related intellectual property and research outcomes [5]. - The results from the feasibility study are expected to inform the design of larger clinical validation studies and support the A+PerfusC platform's use as a predictive tool for treatment response [4]. Group 4: Company Overview - Advanced Biomed Inc. specializes in innovative biomedical technologies for cancer detection and precision medicine, operating through a subsidiary in Taiwan [6][7]. - The company has developed a proprietary microfluidic platform for advanced circulating tumor cell detection, with plans for regulatory clearances in Taiwan and future global expansion [7].

Core Viewpoint - Advanced Biomed (ADVB) has agreed to sell its wholly owned subsidiary, Advanced Biomed Limited, for a total purchase price of $23,000, based on a valuation report [1] Group 1: Transaction Details - The sale involves 100% of the issued and outstanding shares of Advanced Biomed Limited, a Hong Kong company [1] - The transaction is subject to the terms and conditions outlined in the Agreement [1] - The closing of the transaction is set for December 23, with all intellectual property owned by the Hong Kong subsidiary being transferred to the buyer [1] Group 2: Intellectual Property Transfer - All intellectual property owned by Advanced Biomed Limited, including that of its wholly owned subsidiary Shanghai Sglcell Biotech, was included in the sale [1]

Group 1 - Advanced Biomed Inc. has entered into an agreement to sell 100% of its Hong Kong subsidiary for a total purchase price of US$23,000 based on a valuation report [1] - The transaction includes the transfer of all intellectual property owned by the Hong Kong subsidiary, including that of its wholly owned subsidiary, Shanghai Sglcell Biotech Co., Ltd. [2] - The CEO of Advanced Biomed stated that the divestment is part of a strategic realignment to centralize clinical trials in Taiwan due to evolving regulatory requirements in China [3] Group 2 - The company operates through its Taiwan subsidiary, which has developed a proprietary microfluidic platform for advanced circulating tumor cell detection and analysis [4] - The product portfolio includes devices and biochips designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for global expansion [4]

Financial Performance - Net loss for the three-month period ended September 30, 2025, was US$386,901, compared to a net loss of US$265,580 for the same period in 2024, representing a 45.66% increase in loss year-over-year[18]. - The Company reported a net loss of $386,901 for the three-month period ended September 30, 2025, with net cash outflows from operating activities amounting to $610,342[47]. - The net loss for the fiscal year ended June 30, 2025, was $3,258,969, representing a 17% increase from the net loss of $2,782,278 in 2024[146]. - For the three-month period ended September 30, 2025, the net loss was $386,901, compared to a net loss of $265,580 for the same period in 2024, representing a 45.6% increase in losses year-over-year[118]. - The net loss for the year ended June 30, 2025, was $3.3 million, compared to a loss of $2.8 million for the year ended June 30, 2024[156]. Revenue and Expenses - Total operating expenses for the three-month period ended September 30, 2025, were US$523,914, slightly higher than US$520,027 for the same period in 2024, indicating a marginal increase of 0.56%[18]. - For the fiscal year ended June 30, 2025, total operating expenses increased by 19% to $3,021,036 compared to $2,541,572 in 2024[146]. - General and administrative expenses decreased to $287,922 in the three-month period ended September 30, 2025, from $338,324 in 2024, indicating a reduction of 14.8%[118]. - Research and development expenses increased to US$235,992 for the three-month period ended September 30, 2025, compared to US$181,703 for the same period in 2024, marking an increase of 29.87%[18]. - Research and development expenses for the fiscal year ended June 30, 2025, were $909,771, a 3% increase from $880,193 in 2024[149]. Assets and Liabilities - Total assets decreased from US$6,512,343 as of June 30, 2025, to US$6,242,970 as of September 30, 2025, a decline of approximately 4.14%[13]. - Total stockholders' equity decreased from US$3,477,564 as of June 30, 2025, to US$3,004,124 as of September 30, 2025, a decline of approximately 13.63%[13]. - Cash at the end of the period decreased to US$2,656,519 from US$2,903,915 at the beginning of the period, reflecting a net decrease of 8.51%[22]. - Total accounts payable, accruals, and other current liabilities increased to $3,017,018 as of September 30, 2025, from $2,853,317 as of June 30, 2025, marking an increase of approximately 5.7%[95]. - As of September 30, 2025, the company's working capital surplus was $2,799,181, down from $3,143,443 as of June 30, 2025[167]. Financing Activities - The company raised approximately US$5.49 million in net proceeds from its initial public offering, which closed on March 7, 2025[24]. - The Company completed its initial public offering on March 7, 2025, issuing 1,640,000 shares at a price of $4.00 per share, resulting in gross proceeds of $6.56 million[103]. - The Company has the right to issue and sell up to $25 million of its common stock under the ELOC Agreement with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD.[45]. - The Company issued a total of 4,405,625 shares to various stockholders to settle debts amounting to approximately $9.04 million[36]. - For the three-month period ended September 30, 2025, the company recorded net cash generated from financing activities of approximately $0.45 million, mainly from loans and repayments to related parties[179]. Shareholder Information - The Company executed a forward share split on May 16, 2023, resulting in 100,000,000 common shares outstanding[53]. - The Company executed a reverse share split on October 15, 2024, reducing the outstanding shares to 20,000,000[54]. - The Company has a total of 15 million shares subject to the 2023 Stock Incentive Plan, which allows for the granting of stock options to employees and service providers[114]. - As of October 25, 2022, Dr. Yi Lu holds a 33.54% ownership stake in the Company following the reorganization[37]. - The amount due from related party Advance On Ventures Limited was $211 as of September 30, 2025, while the amount due to major stockholders totaled $50,013[115]. Future Plans and Expectations - The Company plans to start clinical research in January 2026, expecting to complete it by June 2026 and obtain the required registration certificate by October 2027[73]. - The company aims to expand into the North American market by January 2026, with site selection and personnel recruitment planned for completion by that date[143]. - The company expects to be in a state of continuous loss for the next two to three years due to ongoing development and regulatory processes[144]. - The company has not generated any revenue from product sales and does not expect to do so until clinical development and regulatory approvals are completed[144]. - The company plans to begin clinical research for the ALCGuard Lung Cancer Early Screening Kit in January 2026, with completion anticipated by June 2026[150]. Accounting and Compliance - The Company’s financial statements are prepared in accordance with U.S. GAAP, assuming continuation as a going concern[43]. - The Company accounts for income taxes using the asset and liability approach, recognizing deferred tax assets based on the likelihood of realization of tax benefits in future years[79]. - The Company has assessed that there are no material subsequent events requiring disclosure from September 30, 2025, through November 19, 2025[131]. - The Company has adopted ASC 842 for operating leases, recognizing right-of-use assets and liabilities based on the present value of lease payments[197]. - Recent accounting pronouncements, specifically ASU 2023-06, are not expected to materially impact the Company's consolidated financial statements[212].

Core Viewpoint - Chinese concept stocks experienced significant gains, with notable increases in share prices for several companies, indicating a positive market sentiment towards these stocks [1] Group 1: Stock Performance - Kuke Music (KUKEY) saw a remarkable increase of 120%, closing at 0.1100, with a trading volume of 4,794.6 thousand [1] - BQ (波奇宠物) rose by 113.73%, closing at 16.970, with a trading volume of 6,299.85 thousand [1] - Meiyantang (美妍堂) increased by 45.04%, closing at 27.760, with a trading volume of 1,703.51 thousand [1] - Advanced Biomed (ADVB) experienced a rise of 24.56%, closing at 0.5671, with a trading volume of 1,576.66 thousand [1] - Blue Mountain Holdings (BMHL) gained 22.80%, closing at 3.770, with a trading volume of 3.75 thousand [1]

Technology Development - Advanced Biomed has developed a microfluidic technology platform for cancer detection, including devices like APre and AC-1000, achieving 96% sensitivity and 99.9% specificity in clinical studies[27]. - APre can deplete approximately 90% of blood cells in 10 minutes and reduce sample volume by over 90%, allowing for faster downstream applications[48][50]. - AC-1000 maintains a capture rate of 76-90% for targeted cells and achieves a leukocyte removal rate of 99.9%, enhancing downstream detection accuracy[53]. - ACellScan can complete on-chip immunostaining in approximately 30 minutes, significantly reducing the total detection time by 4-5 hours compared to conventional methods[58][59]. - The combination of APre and AC-1000 allows for the identification and counting of circulating tumor cells in just 40 minutes, with a high recovery rate[65]. - A+PerfusC is a compact 3D cell culture system that enhances cell viability and drug response accuracy by ensuring uniform nutrient supply and waste removal[75]. - ACellScan's performance study demonstrated high precision in capturing cell images, with less than 2 out of 6,400 images being out-of-focus[58]. - The ACellScan Chip can process up to eight samples simultaneously, completing batch processing in one and a half hours[59]. - The rare cell enrichment system is expected to reduce costs further after mass production, making it suitable for routine liquid biopsy applications[53]. - A+PerfusC system supports up to 12 days of hands-free culture, enhancing cell viability and drug response predictability[76]. - ALCGuard achieved 96% sensitivity and 99.9% specificity in detecting circulating tumor cells during clinical studies[83]. - APre and AC-1000 chips are expected to produce at least 2,500 pieces per month, with quality control ensuring compliance with specifications[92]. - The average tumor cell recovery rate for A+Pre chips was 94%, exceeding the target rate of 90%[94]. - The AC-1000 device integrates semiconductor nano ultra-sensitive biosensors for isolating rare cells, with applications in liquid biopsy[99]. - The company has completed mass production trial tests for the AC-1000 CTC Enrichment chip and is refining the production method for the A+CellScan chip[103]. Clinical Research and Regulatory Approvals - The company plans to initiate clinical research for the ALCGuard Lung Cancer Early Screening Kit in November 2025, with completion of the trial stage anticipated within six months[24]. - APre and AC-1000 have received NMPA clearance, while ASCDrop, ACellScan, and ALCGuard are in the registration application stage[26]. - ALCGuard is a Class III medical device, with clinical research planned to begin in November 2025[79]. - Class II and Class III medical devices require pre-approval registration, while Class I devices are subject to filing administration[159]. - The production license for medical devices is valid for five years and may be renewed six months prior to expiration[162]. - The company is currently applying for NMIP coverage for its product A+LCGuard, which is the only product under consideration for reimbursement[183]. - The application process for NMIP coverage may take one to two years to complete, with no guaranteed approval from NHSA[183]. - The company’s products are not currently covered by any national or provincial medical insurance programs[183]. Market Expansion and Business Strategy - The company aims to expand into the North American market by December 2025, with site selection and personnel recruitment underway[30]. - Advanced Biomed plans to establish subsidiaries in the U.S. and Europe for localized production and registration of its products[29]. - The company plans to develop the cancer screening market in China and expand to North America and Europe by establishing subsidiaries and localizing production[103]. - Advanced Biomed has entered into an ELOC Agreement to raise up to $25 million through the sale of common stock[34]. - The company expects to remain in a state of continuous loss for the next two to three years until clinical development and regulatory approvals are achieved[31]. - The company has completed the acquisition of Advanced Biomed Taiwan and established Advanced Biomed HK for market operations in China[36]. Financial and Operational Challenges - Advanced Biomed is currently not generating revenue and does not expect to do so until clinical trials are completed and products are approved[31]. - The company has no commercial insurance, making it susceptible to losses that could materially impact business operations and financial condition[131]. - The company is required to obtain various licenses and approvals for operations in Taiwan and China, including indefinite business registrations and specific expiration dates for others[130]. - The company has a profit retention tax of 5% on any current earnings that remain undistributed by the end of the following year[151]. Intellectual Property and Research Collaborations - The company has registered or applied for a total of 20 patents related to cancer detection technologies as of June 30, 2025, including 8 patents for novel separation technologies and 6 patents for high throughput droplet microfluidic chips[102]. - The company is actively pursuing intellectual property protection for its core technologies and ongoing research in early-stage cancer screening[104]. - The company has established partnerships with advisors and academic institutions to strengthen its research and development efforts in tumor precision diagnosis[116]. - The company developed ASCDrop based on advisors' recommendations to capture active single cells for clinical applications[119]. - The company entered into two industry-academia cooperation agreements with National Taiwan University for identifying novel biomarkers for early lung cancer detection, with a payment of NTD 6 million in two installments[123][126]. - The Renewed Cooperation Agreement with National Taiwan University requires a payment of NTD 3 million, with the first installment due on December 15, 2024[124][126]. Compliance and Regulatory Environment - The company must comply with M&A Rules when engaging in mergers or acquisitions, requiring approval from the CSRC for overseas listings[186]. - The CSRC has introduced new filing requirements for PRC domestic companies seeking to list securities overseas, effective March 31, 2023[189]. - The company must establish a confidentiality and archives system when offering and listing securities overseas, as per the new regulations effective March 31, 2023[190]. - The valid period for Medical Device Product Export Sales Certificates is no longer than two years, and enterprises must report any changes in relevant materials[185]. - Foreign investments in China are governed by the Industry Guidelines and the Negative List, which classify businesses into "encouraged," "restricted," and "prohibited" categories[191]. - The Negative List prohibits foreign investment in specific sectors, including Internet news services and Internet publishing services[191]. - The Anti-Monopoly Law allows fines of up to RMB500,000 for illegal concentrations, with proposed amendments increasing fines to 10% of last year's sales revenue for serious violations[199]. - The PRC Cybersecurity Law mandates that network operators must obtain consent for collecting personal information and disclose the purposes and methods of data collection[203]. - The Personal Information Protection Law, effective November 1, 2021, requires consent for using sensitive personal information and outlines the rights of individuals regarding their data[210]. - Internet service providers face penalties for failing to manage information security, which can include fines and criminal penalties for severe breaches[202]. - The Measures for Information Reporting on Foreign Investment require foreign investors to submit investment information to the competent commerce department[195]. - The State encourages foreign investments and aims to optimize the investment environment through various regulations[194]. - App operators must clearly state their data collection policies and obtain user consent without coercion, with violations leading to operational penalties[206]. - The company does not engage in user data collection or cybersecurity-related activities, nor does it operate in any foreign investment restricted industries[213]. - The draft regulations on Internet Data Security Management emphasize the obligations of internet platform operators, including immediate remediation measures for security defects and annual data security assessments[212]. Human Resources and Organizational Structure - As of June 30, 2025, the company has 31 employees, with 58% in technology, research, and development roles[112]. - The company has a multi-disciplinary management team and R&D team, combining expertise in semiconductor technology and biomedical fields[103].

Core Insights - Advanced Biomed Inc. has launched the A+PerfusC system, a compact 3D cell culture incubator designed to replicate human physiological conditions in vitro [1][2] - The A+PerfusC platform integrates automated perfusion with environmental control, allowing for up to 12 days of continuous, hands-free culture, which enhances cell viability and drug response predictability [2][5] - The global 3D cell culture market is projected to grow from USD 2.32 billion in 2025 to over USD 4.71 billion by 2030, with a compound annual growth rate of over 15.6% [4] Company Overview - Advanced Biomed Inc. specializes in innovative biomedical technologies for cancer detection and precision medicine, operating through subsidiaries in Taiwan, Hong Kong, and Mainland China [9][10] - The company has developed a proprietary microfluidic platform for advanced circulating tumor cell detection, with regulatory clearances in progress in China and plans for global expansion [10] Product Features - The A+PerfusC system supports up to 8 independent channels per plate, allowing for 600 tumor spheroids per row and a total of 4,800 tumor spheroids per plate [8] - The system is designed for easy transfer into 96 or 384 well plates for high-throughput drug screening and can be mounted on microscopy platforms [8] Future Plans - The company plans to scale up the A+PerfusC system for high-throughput use and integrate imaging with AI-driven analytics to enhance tumor profiling and personalized treatment development [5]

Financial Performance - Total assets increased to $8,287,598 as of March 31, 2025, up from $4,460,247 as of June 30, 2024, representing an 86% growth[12]. - Cash at the end of the period rose to $5,184,100, compared to $2,663,704 at the end of the same period last year, marking a 95% increase[19]. - Net loss for the nine-month period ended March 31, 2025, was $2,557,358, compared to a loss of $1,972,892 for the same period in 2024, reflecting a 30% increase in losses[14]. - Total stockholders' equity increased to $4,129,783 as of March 31, 2025, from $1,663,258 as of June 30, 2024, representing a 148% increase[12]. - The Company reported a net loss of $2,557,358 and net cash outflows of $4,281,093 from operating activities for the nine-month period ended March 31, 2025[37]. - The net loss for the fiscal year ended June 30, 2024, was $2.78 million, a 25% improvement compared to a net loss of $3.73 million in 2023[125]. - The company expects to be in a state of continuous loss for the next two to three years as it has not commenced sales of any products[123]. Research and Development - Research and development expenses decreased to $675,546 for the nine-month period ended March 31, 2025, from $671,081 in the previous year, indicating a slight increase of 0.7%[14]. - The company has not commenced sales of revenue-generating products and does not expect to do so until clinical development and regulatory approvals are completed[66]. - The company developed the ALCGuard Lung Cancer Early Screening Kit, which is a Class III medical device requiring clinical trials before registration, with plans to start clinical research by June 2025[116]. - The company has completed the R&D stage for four immunostaining kits and submitted registration applications in China[115]. - The company reported a 36% decrease in research and development expenses from $1.4 million in 2023 to $0.9 million in 2024, primarily due to a slowdown in clinical development activities[130]. Financing Activities - The company completed its initial public offering on March 7, 2025, issuing 1,640,000 shares at $4.00 per share, raising approximately $6,699,767 in financing activities[21]. - The Company issued 1,640,000 shares of common stock at a price of $4.00 per share, resulting in gross proceeds of $6.56 million before deducting any underwriting discounts or expenses[38]. - The company is exploring additional financing options, including debt and equity, to support its operations and working capital needs[140]. - The company has received waivers from related parties for amounts due totaling $2,820,624 to improve working capital[38]. - The company is in the process of raising debt from related parties, although there is uncertainty regarding the availability of these financings[39]. Operational Efficiency - The Company transferred its inactive subsidiaries at zero consideration to improve operational efficiency, including Nanjing Yitian Biotech Co., Ltd. and Shandong Sglcell Medical Devices Co., Ltd.[24][25]. - Total operating expenses for the nine-month period ended March 31, 2025, were $1,808,495, a decrease from $1,836,959 in the same period of 2024, reflecting a 1.5% reduction[14]. - The Company has implemented cost-cutting measures that are projected to save $5 million annually[211]. - The company has launched a new product line that is expected to contribute an additional $20 million in revenue by the end of the fiscal year[211]. Market Expansion - Advanced Biomed Inc. plans to establish operation centers in North America and Europe to expand its market presence[113]. - The company plans to expand into the North American market, aiming to complete site selection and personnel recruitment by the end of 2025[122]. - Advanced Biomed Inc. plans to enter two new international markets by the end of 2025, aiming to increase its global footprint[211]. Assets and Liabilities - As of March 31, 2025, total prepaid expenses and other current assets increased to $2,547,048 from $443,137 as of June 30, 2024, representing a significant growth of approximately 474%[80]. - Accounts payable and other current liabilities increased to $3,974,986 as of March 31, 2025, compared to $2,670,249 as of June 30, 2024, reflecting an increase of approximately 49%[84]. - The Company reported total net operating loss carry forwards of approximately $10,978,631 as of March 31, 2025, compared to $8,767,393 as of June 30, 2024, indicating an increase of about 25%[92]. - The loan balance due to Well Fancy Development Ltd amounted to approximately US$1,586,860 as of June 30, 2024, which was waived off[99]. - As of March 31, 2025, the total amount due to related parties, including major stockholders, was US$356,759, compared to US$113,812 as of June 30, 2024, reflecting a significant increase[98]. Regulatory and Compliance - The Company’s ability to continue as a going concern depends on its ability to develop and obtain regulatory approval for its products[37]. - The company is in the registration application stage for several products, including ALCGuard, which is currently undergoing the necessary regulatory processes[117]. - The Company accounts for income taxes using the asset and liability approach, recognizing deferred tax assets based on the likelihood of realization of tax benefits in future years[71]. - The Company has not recognized any income tax expense for the three-month and nine-month periods ended March 31, 2025, and 2024, due to operating losses[96]. Strategic Initiatives - Advanced Biomed Inc. reported a significant increase in revenue, achieving $150 million for Q1 2025, representing a 25% year-over-year growth[211]. - The company has expanded its user base to 1.2 million active users, a 30% increase compared to the previous quarter[211]. - Advanced Biomed Inc. projects a revenue growth of 20% for the next quarter, targeting $180 million in Q2 2025[211]. - The company is investing $10 million in R&D for new product development, focusing on innovative biomedicine technologies[211]. - The company is focusing on enhancing customer engagement through digital platforms, aiming for a 15% increase in customer retention rates[211].